Bruno Sarmento is Principal Investigator, Group Leader and member of the Board of Directors at Institute for Research and Innovation in Health (i3S), University of Porto (UP), and Invited Associate Professor at Instituto Universitário de Ciências da Saúde (IUCS), Portugal. He graduated in Pharmaceutical Sciences at the University of Porto (PT) in 2002 and completed a PhD in Pharmaceutical Nanotechnology at UP in 2007, in collaboration with Queen’s University (CA), University of Copenhagen (DK) and University of Santiago de Compostela (ES). From 2007 to 2012 he held a Post-Doc position at UP, in collaboration with the University of Copenhagen. In 2008 he was appointed Assistant Professor at IUCS. He also co-founded Inovapotek in 2008, and is member of its advisory board. In 2012 he became Associated Researcher at INEB, where established an independent team. He was appointed as Assistant Researched at INEB/i3S in 2016, and Principal Investigator in 2019. He was Visiting Professor ay, UniOeste (BR) and Visiting Research Professor at Queen’s University, Belfast (UK). So far, he has supervised/co-supervised 14 Post-Docs (12 completed), 45 PhD students (34 completed) and 38 MSc students (35 completed), and 13 researcher assistants. He attracted direct competitive funding worth more than 15 M€, at national and international levels. His current research is focused on the development of functionalized nanomedicines and their application in the pharmaceutical and biomedical fields. In particular, nanoformulations of biopharmaceutical drugs with interest in diabetes, cancer and infectious diseases. He has also specialized in mucosal tissue engineering models to validate functionalized nanomedicines and to perform in vitro/in vivo correlation. He published 400 papers in international journals, most in top journals (Q1 in Pharmaceutical Sciences; Q1 in Nanoscience and Nanotechnology; total citations in Scopus 13200; H-index 57 and in GoogleScholar 17720; H-index 67), 54 book chapters and more than 350 proceedings. He edited 5 books, participated in more than 50 invited/selected talks in national and international meetings and was awarded several distinctions. He is editor of European Journal of Pharmaceutical Sciences, and member of the Editorial Advisory Board of 11 international journals, including the Journal of Controlled Release, Expert Opinion on Drug Delivery and Pharmaceutics. He has acted as referee for top-ranked journals in his area of expertise, and for international funding agencies: FNRS (BE), Inserm (FR), CNCS (RO), FCT (PT), Foncyt (ARG), CNPq (BR) and European Commission. Bruno Sarmento was the first Chair of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society (CRS) and is now Director-at-Large of CRS and member of CRS Collegue of Fellows. In addition to being a partner in several research projects, he was the PI of competitively funded projects (FCT, Gilead and CESPU), PI of different bilateral collaborative projects between Portugal (FCT) and foreigner funding agencies as well as partner of several European projects funded by European Commission.
Bruno Sarmento is Principal Investigator, Group Leader and member of the Board of Directors at Institute for Research and Innovation in Health (i3S), University of Porto (UP), and Invited Associate Professor at Instituto Universitário de Ciências da Saúde (IUCS), Portugal. He graduated in Pharmaceutical Sciences at the University of Porto (PT) in 2002 and completed a PhD in Pharmaceutical Nanotechnology at UP in 2007, in collaboration with Queen’s University (CA), University of Copenhagen (DK) and University of Santiago de Compostela (ES). From 2007 to 2012 he held a Post-Doc position at UP, in collaboration with the University of Copenhagen. In 2008 he was appointed Assistant Professor at IUCS. He also co-founded Inovapotek in 2008, and is member of its advisory board. In 2012 he became Associated Researcher at INEB, where established an independent team. He was appointed as Assistant Researched at INEB/i3S in 2016, and Principal Investigator in 2019. He was Visiting Professor ay, UniOeste (BR) and Visiting Research Professor at Queen’s University, Belfast (UK). So far, he has supervised/co-supervised 14 Post-Docs (12 completed), 45 PhD students (34 completed) and 38 MSc students (35 completed), and 13 researcher assistants. He attracted direct competitive funding worth more than 15 M€, at national and international levels. His current research is focused on the development of functionalized nanomedicines and their application in the pharmaceutical and biomedical fields. In particular, nanoformulations of biopharmaceutical drugs with interest in diabetes, cancer and infectious diseases. He has also specialized in mucosal tissue engineering models to validate functionalized nanomedicines and to perform in vitro/in vivo correlation. He published 400 papers in international journals, most in top journals (Q1 in Pharmaceutical Sciences; Q1 in Nanoscience and Nanotechnology; total citations in Scopus 13200; H-index 57 and in GoogleScholar 17720; H-index 67), 54 book chapters and more than 350 proceedings. He edited 5 books, participated in more than 50 invited/selected talks in national and international meetings and was awarded several distinctions. He is editor of European Journal of Pharmaceutical Sciences, and member of the Editorial Advisory Board of 11 international journals, including the Journal of Controlled Release, Expert Opinion on Drug Delivery and Pharmaceutics. He has acted as referee for top-ranked journals in his area of expertise, and for international funding agencies: FNRS (BE), Inserm (FR), CNCS (RO), FCT (PT), Foncyt (ARG), CNPq (BR) and European Commission. Bruno Sarmento was the first Chair of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society (CRS) and is now Director-at-Large of CRS and member of CRS Collegue of Fellows. In addition to being a partner in several research projects, he was the PI of competitively funded projects (FCT, Gilead and CESPU), PI of different bilateral collaborative projects between Portugal (FCT) and foreigner funding agencies as well as partner of several European projects funded by European Commission.
Collaborator